210 related articles for article (PubMed ID: 26211680)
21. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
Gurney ME; D'Amato EC; Burgin AB
Neurotherapeutics; 2015 Jan; 12(1):49-56. PubMed ID: 25371167
[TBL] [Abstract][Full Text] [Related]
22. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.
Ricciarelli R; Brullo C; Prickaerts J; Arancio O; Villa C; Rebosio C; Calcagno E; Balbi M; van Hagen BT; Argyrousi EK; Zhang H; Pronzato MA; Bruno O; Fedele E
Sci Rep; 2017 Apr; 7():46320. PubMed ID: 28402318
[TBL] [Abstract][Full Text] [Related]
23. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown.
Houslay MD
Trends Biochem Sci; 2010 Feb; 35(2):91-100. PubMed ID: 19864144
[TBL] [Abstract][Full Text] [Related]
24. Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture.
Méhats C; Tanguy G; Dallot E; Robert B; Rebourcet R; Ferré F; Leroy MJ
Endocrinology; 1999 Jul; 140(7):3228-37. PubMed ID: 10385419
[TBL] [Abstract][Full Text] [Related]
25. PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Kenk M; Thomas A; Lortie M; Dekemp R; Beanlands RS; Dasilva JN
Curr Radiopharm; 2011 Jan; 4(1):44-58. PubMed ID: 22191614
[TBL] [Abstract][Full Text] [Related]
26. RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-β42-induced memory deficits in mice.
Zhang C; Cheng Y; Wang H; Wang C; Wilson SP; Xu J; Zhang HT
J Alzheimers Dis; 2014; 38(2):269-80. PubMed ID: 23948935
[TBL] [Abstract][Full Text] [Related]
27. Cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase is functional in bovine mammary gland.
Dostaler-Touchette V; Bédard F; Guillemette C; Pothier F; Chouinard PY; Richard FJ
J Dairy Sci; 2009 Aug; 92(8):3757-65. PubMed ID: 19620657
[TBL] [Abstract][Full Text] [Related]
28. Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations.
Furlan V; Bren U
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33806914
[TBL] [Abstract][Full Text] [Related]
29. Protein-protein interactions of PDE4 family members - Functions, interactions and therapeutic value.
Klussmann E
Cell Signal; 2016 Jul; 28(7):713-8. PubMed ID: 26498857
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors.
Brullo C; Rapetti F; Abbate S; Prosdocimi T; Torretta A; Semrau M; Massa M; Alfei S; Storici P; Parisini E; Bruno O
Eur J Med Chem; 2021 Nov; 223():113638. PubMed ID: 34171658
[TBL] [Abstract][Full Text] [Related]
32. PDE4 inhibitors for disease therapy: advances and future perspective.
Du B; Luo M; Ren C; Zhang J
Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
[TBL] [Abstract][Full Text] [Related]
33. Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance.
Motte E; Le Stunff C; Briet C; Dumaz N; Silve C
Mol Cell Endocrinol; 2017 Feb; 442():1-11. PubMed ID: 27908835
[TBL] [Abstract][Full Text] [Related]
34. Adaptive phenotypic modulation of human arterial endothelial cells to fluid shear stress-encoded signals: modulation by phosphodiesterase 4D-VE-cadherin signalling.
Rampersad SN; Wudwud A; Hubert F; Maurice DH
Cell Signal; 2016 Jul; 28(7):741-8. PubMed ID: 26658094
[TBL] [Abstract][Full Text] [Related]
35. Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells.
Kim MJ; Park SK; Lee JH; Jung CY; Sung DJ; Park JH; Yoon YS; Park J; Park KG; Song DK; Cho H; Kim ST; Koo SH
Diabetes; 2015 Sep; 64(9):3189-202. PubMed ID: 25918234
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of phosphodiesterase-4 subtypes involved in surgery-induced neuroinflammation and cognitive dysfunction in mice.
Wang W; Zhang XY; Feng ZG; Wang DX; Zhang H; Sui B; Zhang YY; Zhao WX; Fu Q; Xu ZP; Mi WD
Brain Res Bull; 2017 Apr; 130():274-282. PubMed ID: 28235598
[TBL] [Abstract][Full Text] [Related]
37. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase 4B: Master Regulator of Brain Signaling.
Tibbo AJ; Baillie GS
Cells; 2020 May; 9(5):. PubMed ID: 32438615
[TBL] [Abstract][Full Text] [Related]
40. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
